Exton, PA, July 13, 2020

Megna Health, a medical technology company based in Exton, PA, announces results from independent validation of its Rapid COVID-19 Antibody IgG / IgM Test by NIH / NCI (National Cancer Institute) coordinated by FDA.

Results show sensitivity of 100% for IgG, and IgG /IgM combined; Combined specificity of 95%.

Click here for the full NIH/NCI report.  Please contact info@megnahelath.com if you have any questions.